Corcept Therapeutics (CORT) Change in Receivables (2012 - 2026)

Corcept Therapeutics has disclosed Change in Receivables across 15 years of filings, most recently posting -$20.7 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$20.7 million, down 364.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.7 million (down 7657.14% YoY), and the FY2025 annual result was $5.8 million, down 54.8% from the prior year.
• Change in Receivables came in at -$20.7 million for Q1 2026 at Corcept Therapeutics, down from -$9.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.4 million in Q1 2024 to a low of -$20.7 million in Q1 2026.
• The 5-year median for Change in Receivables is $1.5 million (2023), against an average of $673352.9.
• Peak annual rise in Change in Receivables reached 1259.67% in 2024, while the deepest fall reached 191925.0% in 2024.
• Corcept Therapeutics' Change in Receivables stood at $1.6 million in 2022, then surged by 295.44% to $6.5 million in 2023, then slumped by 188.36% to -$5.7 million in 2024, then tumbled by 71.45% to -$9.8 million in 2025, then sank by 110.44% to -$20.7 million in 2026.
• The last three Change in Receivables figures came in at -$20.7 million (Q1 2026), -$9.8 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.